United Therapeutics UTHR Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $3.18B+10.6% | $2.88B+23.6% | $2.33B+20.2% | $1.94B+14.9% | ||
| $384.4M+24.1% | $309.7M+20.3% | $257.5M+69.9% | $151.6M+23.8% | ||
| $2.8B+9.0% | $2.57B+24.0% | $2.07B+16.0% | $1.78B+14.2% | ||
| 87.9%-1.3pp | 89.2%+0.3pp | 88.9%-3.2pp | 92.2%-0.6pp | ||
| $550M+14.3% | $481M+17.9% | $408M+26.4% | $322.9M-40.2% | ||
| $755.8M+6.5% | $709.7M+48.8% | $477.1M-1.0% | $482.1M+3.2% | ||
| $1.69B+12.6% | $1.5B+31.3% | $1.14B+19.4% | $956.6M-15.3% | ||
| $1.49B+8.4% | $1.38B+16.2% | $1.18B+20.9% | $979.7M+76.2% | ||
| 46.9%-1.0pp | 47.9%-3.1pp | 50.9%+0.3pp | 50.6%+17.6pp | ||
| $19.5M-54.5% | $42.9M-27.7% | $59.3M+83.0% | $32.4M+74.2% | ||
| $221.4M+36.7% | $162M+81.2% | $89.4M— | —— | ||
| $1.71B+11.4% | $1.54B+20.8% | $1.27B+34.1% | $950.6M+60.1% | ||
| $379.2M+10.3% | $343.9M+18.8% | $289.5M+29.6% | $223.3M+89.1% | ||
| $1.33B+11.7% | $1.2B+21.4% | $984.8M+35.4% | $727.3M+52.9% | ||
| 41.9%+0.4pp | 41.5%-0.8pp | 42.3%+4.8pp | 37.6%+9.3pp | ||
| $27.89+13.3% | $24.62+24.3% | $19.81+32.1% | $15.00+49.7% | ||
| $1.58B+8.9% | $1.45B+17.1% | $1.24B+20.1% | $1.03B+70.2% | ||
| 49.6%-0.8pp | 50.4%-2.8pp | 53.2%-0.1pp | 53.2%+17.3pp | ||
| $1.49B+8.4% | $1.38B+16.2% | $1.18B+20.9% | $979.7M+76.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is United Therapeutics's revenue?
- United Therapeutics (UTHR) generated $3.2B in revenue over the trailing twelve months, up 5.9% year over year.
- Is United Therapeutics profitable?
- United Therapeutics reported $1.3B in net income over the trailing twelve months, a 40.6% net margin.
- What are United Therapeutics's profit margins?
- Gross margin is 86.6% and operating margin is 45.3%, with a 40.6% net margin.
- What is United Therapeutics's earnings per share?
- United Therapeutics's diluted EPS over the trailing twelve months is $27.08.
- Where does United Therapeutics's income statement data come from?
- Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
